150 related articles for article (PubMed ID: 33495907)
1. Humoral immune response to epidermal growth factor receptor in lung cancer.
Wang Y; Liu F; OuYang S; Liu M; Zhang X; Wang P; Zhao C; Zhang L; Dai L
Immunol Res; 2021 Feb; 69(1):71-80. PubMed ID: 33495907
[TBL] [Abstract][Full Text] [Related]
2. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
3. Identification of tumor-associated antigens of lung cancer: SEREX combined with bioinformatics analysis.
Wang Y; Wang P; Liu M; Zhang X; Si Q; Yang T; Ye H; Song C; Shi J; Wang K; Wang X; Zhang J; Dai L
J Immunol Methods; 2021 May; 492():112991. PubMed ID: 33587914
[TBL] [Abstract][Full Text] [Related]
4. Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer.
Wang T; Liu H; Pei L; Wang K; Song C; Wang P; Ye H; Zhang J; Ji Z; Ouyang S; Dai L
Clin Immunol; 2020 Jan; 210():108262. PubMed ID: 31629809
[TBL] [Abstract][Full Text] [Related]
5. A Diagnostic Model With IgM Autoantibodies and Carcinoembryonic Antigen for Early Detection of Lung Adenocarcinoma.
Zhang X; Li J; Wang Y; Liu M; Liu F; Zhang X; Pei L; Wang T; Jiang D; Wang X; Zhang J; Dai L
Front Immunol; 2021; 12():728853. PubMed ID: 35140701
[TBL] [Abstract][Full Text] [Related]
6. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
Sun N; Chen Z; Tan F; Zhang B; Yao R; Zhou C; Li J; Gao Y; Liu Z; Tan X; Zhou F; He MY; Shao K; Li N; Qiu B; Sun J; Yu Y; Wang S; Zhao Y; Shi X; He J
Clin Cancer Res; 2013 Sep; 19(18):5136-45. PubMed ID: 24046070
[TBL] [Abstract][Full Text] [Related]
7. Roles of immunohistochemical staining in diagnosing pulmonary squamous cell carcinoma.
Yan Y; Zhang YX; Fang WF; Kang SY; Zhan JH; Chen N; Hong SD; Liang WH; Tang YN; He DC; Wu X; Zhang L
Asian Pac J Cancer Prev; 2015; 16(2):551-7. PubMed ID: 25684486
[TBL] [Abstract][Full Text] [Related]
8. Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Pan JB; Hou YH; Zhang GJ
Asian Pac J Cancer Prev; 2013; 14(2):695-700. PubMed ID: 23621221
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.
Gao Y; Song P; Li H; Jia H; Zhang B
BMC Cancer; 2017 Jul; 17(1):484. PubMed ID: 28705152
[TBL] [Abstract][Full Text] [Related]
10. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
Wang WT; Li Y; Ma J; Chen XB; Qin JJ
Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
[TBL] [Abstract][Full Text] [Related]
11. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
12. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
Dong J; Zeng BH; Xu LH; Wang JY; Li MZ; Zeng MS; Liu WL
J Transl Med; 2010 Sep; 8():81. PubMed ID: 20813067
[TBL] [Abstract][Full Text] [Related]
13. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
Jiang R; Wang X; Li K
Oncotarget; 2016 May; 7(18):26823-36. PubMed ID: 27072585
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Zhang Y; Jin B; Shao M; Dong Y; Lou Y; Huang A; Han B
Tumour Biol; 2014 May; 35(5):4921-8. PubMed ID: 24459065
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in the lung cancer diagnosis: a clinical perspective.
Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M
Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014
[TBL] [Abstract][Full Text] [Related]
18. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
[TBL] [Abstract][Full Text] [Related]
19. Correlation between pre-treatment serum carcinoembryonic antigen levels and genotypes in a large population of Chinese people with advanced lung adenocarcinoma.
Liu J; Zhao YQ; Han X; Hu XF; Wu HB; Chen LJ; Song YP
Intern Med J; 2019 May; 49(5):634-643. PubMed ID: 30379408
[TBL] [Abstract][Full Text] [Related]
20. Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients.
Molinier O; Goupil F; Debieuvre D; Auliac JB; Jeandeau S; Lacroix S; Martin F; Grivaux M
Respir Med Res; 2020 Mar; 77():46-54. PubMed ID: 32036284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
